Structural and functional characterization of B-domain deleted recombinant factor VIII.
A new high-purity recombinant factor VIII preparation has been developed for the treatment of hemophilia A. Structurally, this factor VIII preparation, B-domain deleted recombinant factor VIII (BDDrFVIII), differs from other recombinant and plasma-derived factor VIII preparations in that most of the B-domain has been deleted. To ensure that BDDrFVIII contains the requisite structural and functional features, it has been subjected to detailed biochemical and biophysical characterization in comparison to the plasma-derived form of factor VIII. Laboratory studies have shown that the primary, secondary, and tertiary structures of BDDrFVIII and the posttranslational modifications are similar to those of the [80 + 90]-kd form of plasma-derived factor VIII. In addition, BDDrFVIII has full biologic activity compared with full-length factor VIII preparations.
Sandberg
H
H
Pharmacia AB, Stockholm, Sweden.
Almstedt
A
A
Brandt
J
J
Castro
V M
VM
Gray
E
E
Holmquist
L
L
Lewin
M
M
Oswaldsson
U
U
Mikaelsson
M
M
Jankowski
M A
MA
Bond
M
M
Scoble
H A
HA
D000595:Amino Acid Sequence; D004347:Drug Interactions; D005169:Factor VIII / Q000737:chemistry* / Q000378:metabolism*; D006801:Humans; D008969:Molecular Sequence Data; D011485:Protein Binding
C427184:recombinant factor VIII SQ; D005169:Factor VIII